MYC-ATF4-ASS1 axis governs intracellular arginine synthesis and dictates the immune microenvironment in melanoma

Drug resistance is a major challenge for both targeted therapies and immunotherapies in cancer. Arginine starvation has proven a promising strategy to overcome recurrent tumors. However, key molecules involved and how immune responses are elicited are not well understood. Here we identify in melanoma cells MYC-ATF4-ASS1 signaling as a pathway, which not only governs intracellular arginine synthesis but also modulates antitumor immunity. ATF4 knockout in melanoma cells phenocopied ASS1 knockout in the same cells, both showing greater sensitivity to arginine depletors such as ADI-PEG20. A combination strategy of BRAF/MEK inhibitors and an arginine depletor shows significant therapeutic effects in a immune-compromised mouse model. Both Atf4 and Ass1 knockout melanomas exhibited enhanced infiltration of Cd8+ T cells and significantly reduced tumor growth in a syngeneic mouse model. Single cell transcriptomics profiled the reshaped tumor microenvironment and revealed that a subset of resident macrophages were reprogrammed by endogenous arginine blockade. Overall, our findings reveal that the MYC-ATF4-ASS1 axis not only controls arginine vulnerability of melanomas but also shapes the immune microenvironment.